Research on Non-Hodgkin Lymphoma Discussed by Researchers at Hospital do Cancer de Muriae (Lomustine, Etoposide And Cyclophosphamide in Conditioning Regimen For Lymphomas: Final Analysis).

Researchers at Hospital do Cancer de Muriae conducted a study comparing the outcomes of patients with lymphoma who received a conditioning regimen with Lomustine, Etoposide, and Cyclophosphamide (LEC) for autologous stem cell transplantation to those who underwent another regimen (CBV). The study found that the LEC protocol was safe and showed higher overall survival rates at 24 months compared to the CBV group. However, due to a shortage of lomustine and carmustine in Brazil, new alternative protocols will be necessary. This research provides valuable insights into effective treatment options for patients with lymphoma. [Extracted from the article]